For the year ending 2025-12-31, CRDF made $593K in revenue. -$45,876K in net income. Net profit margin of -7736.26%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Royalty revenues | 593 | 683 | ||
| Research and development | 35,329 | 36,852 | ||
| Selling, general and administrative | 14,224 | 12,482 | ||
| Total operating expenses | 49,553 | 49,334 | ||
| Loss from operations | -48,960 | -48,651 | ||
| Interest income | 3,104 | 3,259 | ||
| Other income (expense), net | 5 | -39 | ||
| Total other income (expense), net | 3,109 | 3,220 | ||
| Net loss | -45,851 | -45,431 | ||
| Preferred stock dividend payable on series a convertible preferred stock | 25 | 24 | ||
| Net loss attributable to common stockholders | -45,876 | -45,455 | ||
| Basic EPS | -0.69 | -0.95 | ||
| Diluted EPS | -0.69 | -0.95 | ||
| Basic Average Shares | 66,841,000 | 47,650,000 | ||
| Diluted Average Shares | 66,841,000 | 47,650,000 | ||
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)